key: cord-0841859-2ofl2048
authors: Pivniouk, Vadim; Pivniouk, Oksana; DeVries, Avery; Uhrlaub, Jennifer L.; Michael, Ashley; Pivniouk, Denis; VanLinden, Sydney R.; Conway, Michelle Y.; Hahn, Seongmin; Malone, Sean P.; Ezeh, Peace; Churko, Jared M.; Anderson, Dayna; Kraft, Monica; Nikolich-Zugich, Janko; Vercelli, Donata
title: The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression
date: 2021-12-10
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2021.11.019
sha: 04b7a589b7d823fe339a3848a4f744aa7d0a17de
doc_id: 841859
cord_uid: 2ofl2048

Background Treatments for coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), are urgently needed but remain limited. SARS-CoV-2 infects cells through interactions of its spike (S) protein with ACE2 and TMPRSS2 on host cells. Multiple cells and organs are targeted, particularly airway epithelial cells. OM-85, a standardized lysate of human airway bacteria with strong immunomodulating properties and an impeccable safety profile, is widely used to prevent recurrent respiratory infections. We found that airway OM-85 administration inhibits Ace2 and Tmprss2 transcription in the mouse lung, suggesting that OM-85 might hinder SARS-CoV-2/host cell interactions. Objectives To investigate whether and how OM-85 treatment protects non-human primate and human epithelial cells against SARS-CoV-2. Methods ACE2 and TMPRSS2 mRNA and protein expression, cell binding of SARS-CoV-2 S1 protein, cell entry of SARS-CoV-2 S protein-pseudotyped lentiviral particles, and SARS-CoV-2 cell infection were measured in kidney, lung and intestinal epithelial cell lines, primary human bronchial epithelial cells, and ACE2-transfected HEK293T cells treated with OM-85 in vitro. Results OM-85 significantly downregulated ACE2 and TMPRSS2 transcription and surface ACE2 protein expression in epithelial cell lines and primary bronchial epithelial cells. OM-85 also strongly inhibited SARS-CoV-2 S1 protein binding to, SARS-CoV-2 S protein-pseudotyped lentivirus entry into, and SARS-CoV-2 infection of epithelial cells. These effects of OM-85 appeared to depend on SARS-CoV-2 receptor downregulation. Conclusion OM-85 inhibits SARS-CoV-2 epithelial cell infection in vitro by downregulating SARS-CoV-2 receptor expression. Further studies are warranted to assess whether OM-85 may prevent and/or reduce the severity of COVID-19.

The To obtain human primary airway cells, participants were recruited from the population in 146

Tucson, Arizona and the surrounding areas. Before undergoing any procedure, 147 informed consent according to an Institutional Review Board-approved protocol was 148 obtained from each participant. Healthy participants had no evidence of airway 149 obstruction and no history of pulmonary disease; atopy (as determined by clinical 150 history, allergen skin testing and blood eosinophil levels) was not an exclusion criterion. 151

Participants underwent bronchoscopy with endobronchial-protected brushing, as 152 previously described 18 . To obtain bronchial epithelial cells, brushing of the proximal 153 airways was performed using a separate protected cytologic brush for each pass, for a 154 total of ten passes. Participants were discharged after their forced expiratory volume in 155 with 1% BSA and 0.1% NaN3) at 0.5-1x10 7 cells/ml. To block nonspecific staining, cells 176

were incubated on ice for 10 min in the same buffer containing normal rat serum (2%) 177 followed by a 30 min incubation with recombinant His-tagged S1 protein (5.625 g/ml: Tmprss2 expression was also decreased, albeit not significantly (Fig. 1B) . with Ace2-and Tmprss2-specific primers was then used to measure lung expression of 265 these genes and compare their mRNA levels at day 34 and 39 of our protocol (i.e., 2 266 and 7 days after the last OM-85 treatment: Fig. 1A) . We chose the 7-day time point 267 because it was optimal for inhibition of experimental allergic asthma and was used to 268 generate the RNA-seq data presented here 17 . On the other hand, the 2-day time point 269 allowed us to explore shorter-term effects. Relative to PBS-treated mice, Tmprss2 was 270 significantly downregulated at both time points (P=0.01 and P=0.003, respectively: Fig.  271 1D), whereas Ace2 was significantly (P=0.01) inhibited only at the earlier time point 272 (Fig. 1C) . These experiments showed that delivery of OM-85 to the airways affected the 273 expression of the major SARS-CoV-2 receptor components in the lung, with distinct 274 time-dependent effects. 275

Because OM-85 is a bacterial lysate whose ability to protect from asthma in vivo 276 depends on Myd88/Trif innate immune signaling 17 , we then assessed whether OM-85-277 induced inhibition of Ace2 and Tmprss2 transcription in the mouse lung also required 278 this pathway. These experiments, which were performed in C57BL/6 mice, revealed that 279 as few as four i.n. treatments with OM-85 (1 mg/treatment: Fig. E1A ) were sufficient to 280 reduce Ace2 and Tmprss2 expression by 59% and 63%, respectively, in lung cells 281 isolated from wild-type (WT) mice. In contrast, negligible changes in the expression of 282 these genes were detected in Myd88 -/-Trif -/mice (Fig. E1B) . These findings indicated 283 that OM-85-induced downregulation of Ace2 and Tmprss2 transcription in mouse lung 284 tissue is Myd88/Trif-dependent and strain-independent. 285 To further explore the significance of our findings, we turned to human primary airway 311 cells, a pre-eminent natural SARS-CoV-2 target. Bronchial epithelial cells isolated from 312 a healthy individual were differentiated at the air-liquid interface for 2 weeks. ACE2 and 313 TMPRSS2 mRNA levels were then measured by RT-qPCR after a 48-or 72-hour 314 incubation with PBS or OM-85 (1.92 mg/ml). Fig. 3 shows strong, significant inhibition of 315 CoV-2 receptor expression on epithelial cells from distinct organs. 329

and TMPRSS2 enable SARS-CoV-2 infection of epithelial cell by mediating S protein 331 attachment to, and viral entry into these cells, we next investigated whether OM-85-332 induced downregulation of ACE2 and TMPRSS2 interferes with these processes. To 333 assess the effects of OM-85 on SARS-CoV-2 S protein attachment, we developed an 334 S1 protein binding assay. Cells were incubated with a recombinant His-tagged S1 335 subunit comprising the SARS-CoV-2 receptor binding domain 3 , followed by a 336 phycoerythrin (PE)-conjugated anti-His antibody. S1 protein binding to cells was 337 assessed by flow cytometry. We validated the ability of this assay to specifically detect 338 ACE2-mediated S1 protein cellular binding using HEK293T cells, untransfected or 339 stably transfected with human ACE2 (ACE2/HEK293T). S1 binding was detected in only 340 5% of untransfected HEK293T cells and ACE2/HEK293T cells incubated with anti-His-341 PE antibody without S1 protein, while >99% of PBS-treated ACE2/HEK293T cells 342 bound S1 protein (Fig. 5A) . 343

Using this S1 protein binding assay, we then found that a substantial proportion of Vero 344 E6 (22 ± 0.5%) and Calu-3 (24 ± 1%) epithelial cells bound SARS-CoV-2 S1 protein 345 (Fig. 5B) . Preliminary dose-response curves with a broad range of OM-85 346 concentrations (0.12 to 1.92 mg/ml) showed dose-dependent inhibition of S1 binding to 347

Vero E6 cells, with significant effects (P=7.00E-07) even at the lowest concentration 348 (0.12 mg/ml) and robust inhibition at concentrations ≥ 0.48 mg/ml (Fig. E3) . A 72-hour 349 incubation with OM-85 (0.48 or 1.92 mg/ml) dose-dependently reduced S1 binding by 350 42 ± 4% (P=8E-05) and 53 ± 1.3% (P=1E-10) for Vero E6 cells, and 29 ± 5.6% 351 (P=0.009) and 71 ± 2.3% (P=6E-05) for Calu-3 cells (Fig. 5C) . 352

These results demonstrated that OM-85 efficiently inhibited S1 protein attachment to 353 epithelial cells derived from natural SARS-CoV-2 target organs. Mechanistically, our 354 findings strongly suggested that this inhibition reflected OM-85-dependent interference 355 with the physiologic regulation of ACE2 expression. In support of this notion, even a 356 maximal concentration of OM-85 (1.92 mg/ml) failed to inhibit ACE2 protein expression 357 on (Table E1) , and S1 protein binding to (Fig. 5A, right) , ACE2/HEK293T cells in which 358 human ACE2 transcription is driven by a heterologous, OM-85-unresponsive 359 cytomegalovirus promoter. 360

receptor expression in, and SARS-CoV-2 S1 protein attachment to, epithelial cells also 363 reduces S protein-mediated SARS-CoV-2 entry into these cells, we directly measured 364 the entry of replication-deficient, SARS-CoV-2 S protein-pseudotyped lentiviral particles 365 into epithelial cells pre-incubated with OM-85 or PBS. Our lentiviral particles carried a 366 GFP reporter gene that is transcribed and translated by transduced cells, and were 367 pseudotyped with SARS-CoV-2 S protein or the G glycoprotein of the pantropic 368 vesicular stomatitis virus (VSV: positive transduction control) 3 . As expected, VSV-G-369 pseudotyped particles efficiently transduced Vero E6 cells, with functional titers 370 reaching 2.3x10 6 transducing units (TU)/ml (Fig. 6A, top right) . Vero E6 transduction 371 by SARS-CoV-2-pseudotyped particles was less efficient but still robust and consistent 372 (Fig. 6A, top left) , with titers reaching 1x10 4 TU/ml. 373 OM-85 pre-treatment (0.48 mg/ml) strongly (P=2.5E-05) inhibited SARS-CoV-2 S 374 protein-mediated Vero E6 cell transduction (Fig. 6A, left, and Fig. 6B ). This effect was 375 specific because transduction by VSV-G-pseudotyped particles remained unaffected 376 ( Fig. 6A, right, and Fig. 6C) . The effects of OM-85 on viral entry into Calu-3 cells could 377 not be reliably estimated because these cells were poorly transduced under our 378 experimental conditions. Indeed, both percentages of GFP + cells and GFP MFI in these 379 cells were consistently low following transduction with either SARS-CoV-2 S protein-or 380 VSV-G (positive control) pseudotyped particles (not shown). Notably, ACE2/HEK293T 381 cells were readily transduced by both SARS-CoV-2 S-and VSV-G-pseudotyped viral 382

particles, but OM-85 failed to inhibit viral entry into these cells (Fig. 6D-E) . Because 383 ACE2/HEK293T cells do not downregulate ACE2 upon OM-85 stimulation (Table E1) , 384 these findings were consistent with the notion that OM-85-induced suppression of 385 events leading to SARS-CoV-2 infection involves a reduction of ACE2 expression. 386

The 387 data discussed above had shown that OM-85 effectively inhibits both SARS-CoV-2 S 388 protein attachment and S protein-mediated pseudotyped virus entry into epithelial cells. 389 Therefore, the last set of experiments assessed whether OM-85 treatment also 390 suppressed epithelial cell infection with live SARS-CoV-2. To this end, kidney-derived 391

Vero cells were pretreated with PBS or OM-85 (0.24 to 1.92 mg/ml) for 72 or 96 hours 392 and then incubated for 2 hours with SARS-CoV-2 (isolate USA-WA1/2020). Numbers of 393 pfus/well were counted four days later (Fig. 7A) . SARS-CoV-2 infection was strongly 394 and significantly inhibited in cultures pre-treated with OM-85 for 72 hours (Fig. 7C ) or 96 395 hours ( Fig. E4) but not in PBS-pre-treated cultures. Inhibition was evident even at the 396 lowest OM-85 concentration and reflected effects of OM-85 pretreatment on epithelial 397

cultures that did or did not receive OM-85 during the 2-hour infection period (not 399 shown). SARS-CoV-2 infection of lung-derived Calu-3 cells was also significantly 400 inhibited by a 72-hour pretreatment with OM-85, especially at the highest concentrations 401 of bacterial lysate ( Fig. 7B and D) . These results clearly demonstrate that OM-85 402 inhibits in vitro SARS-CoV-2 infection of epithelial cells sourced from distinct tissues. Our findings have translational implications because the COVID-19 pandemic is not 420 abating and the therapeutic arsenal against COVID-19 is expanding but remains limited. 421

In addition to corticosteroids 29, 30 , biologics that interfere with selected pro-inflammatory 422 pathways (e.g., IL-6, IL-1, Janus kinase inhibitors) 31-33 and anti-SARS-CoV-2 antibodies 423 aimed at disrupting progression of COVID-19 infection 34, 35 , seek to induce humoral and cellular immune responses against the SARS-CoV-2 S 425 protein so as to neutralize its ability to latch onto cellular receptors and mediate 426 infection 36, 37 . Despite their remarkable overall efficacy, though, vaccines remain 427 cumbersome to distribute and administer. Moreover, viral variants of concern may 428 emerge that resist or even escape the immunity generated by the current vaccines 11, 37 . Ace2 and Tmprss2 expression in the lungs of Balb/c mice treated i.n. with OM-85 or 588 PBS as in panel A was measured by RT-qPCR at day 34 or 39 (i.e., 2 or 7 days after 589 the last OM-85 treatment, respectively; n=9-10 mice/group at day 2, and n=7-8 590 mice/group at day 7). mRNA levels normalized by Gapdh are shown relative to PBS. A 591

Wilcoxon two-sample test was used for statistical analysis after testing for normality of 592 sample distribution. 593 recombinant His-tagged S1 protein, followed by an anti-His-PE antibody. S1 binding 626 was assessed by flow cytometry. (C) Effects of OM-85 on S1 protein binding to Vero E6 627 or Calu-3 cells. Data are shown as percentages of S1 protein-binding cells in OM-85-628 treated versus PBS-treated cultures [n=5-6 wells/group from three (Vero E6 cells) or two 629 (Calu-3 cells) independent experiments]. An unpaired, two-tailed t test was used for 630 statistical analysis after testing for normality of sample distribution. 631 Table E .1: Effect of OM-85 on human ACE2 expression by ACE2/HEK293T cells. Cells were treated with PBS or OM-85 (1.92 mg/ml) for 72 hours, and human ACE2 expression was evaluated by flow cytometry with an AF647-conjugated anti-human ACE2 antibody or isotype control. Data are shown as mean percentages ± SE of ACE2-positive cells in PBS-or OM-85treated cultures (n=3/condition). Negligible proportions of positive cells were detected in the trimming adapter sequences) were mapped to the BALB/cJ genome (version mm10) 23 using STAR 1 , and genomic coordinates were shifted to the standard mm10 genome 24 using MARGE (http://cistrome.org/MARGE/index. html). Uniquely aligning reads were 25 used to generate gene counts relying on HOMER 26 (http://homer.ucsd.edu/homer/index.html). Latent factors potentially introducing 27 unwanted variation were removed using RUVSeq 2 . Data for Ace2 and Tmprss2 28 expression in OM-85-and PBS-treated mice were extracted from DESeq2-normalized 29 counts 3 , and P-values from differential expression analysis (DESeq2) were reported. P-30 values < 0.05 were considered significant. 31 RNA extraction, cDNA synthesis and RT-qPCR RNA from cell lines or mouse lung 32 tissue was extracted with the RNeasy kit (Qiagen, Germantown, MD). After extraction, 33 total RNA (500 ng) was used as a template to synthesize cDNA with the QuantiTect 34

Reverse Transcription Kit (Qiagen). RT-qPCR was carried out using the QuantiTect 35 SYBR Green PCR kit (Qiagen) on an ABI 7900 Applied Biosystems thermocycler 36 (ThermoFisher Scientific). All genes except African green monkey (Chlorocebus 37 sabaeus) TMPRSS2 were amplified using commercially available primers (QuantiTect 38

Primer Assays, Qiagen). For green monkey TMPRSS2, the following primers were 39 used: TGCATCAGCTCCTCTAACTG (forward) and GAGATGAGTACACCTGAAGG 40 (reverse). Each sample was run in triplicate. The change in gene expression relative to 41 PBS was normalized to glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and 42 calculated using the 2 -ΔΔct method 4 . 43

Flow cytometry evaluation of ACE2 expression Vero E6 and Calu-3 cells were 44 grown in 12-well plates until confluent and treated with OM-85 (0.48 or 1.92 mg/ml) or 45 nonspecific staining, cells were incubated on ice for 10 min in the same buffer 48 containing normal mouse serum (5%) followed by a 30 min incubation with either mouse 49 anti-human ACE2-PE (Sino Biological, clone 36 5, 6 , for Vero E6 cells), or mouse anti-50 human ACE2-AF647 (R&D Systems, Minneapolis, MN: clone 535919 7-11 , for Calu-3 51 cells). We further validated the ACE2-specificity of these monoclonal antibodies by 52

showing that they detected >99% of ACE2-transfected HEK293T cells, but <1% of 53 parental, untransfected HEK293T cells. 20,000-30,000 events were acquired on a 54

FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo software 55 (Version 10.6.0, Becton Dickinson, 2019). 56

Statistical analyses Statistical differences between treatment groups were assessed 57 by an unpaired, two-tailed t test or a Wilcoxon two-sample test after assessing the 58 normality of sample distribution using the Shapiro-Wilk test. P values <0.05 were 59 considered statistically significant. Analyses were conducted in Stata (version 14.2), R 60 (version 3.5.0), GraphPad Prism (version 9.1.1) and Microsoft Excel. 61 J o u r n a l P r e -p r o o f

Coronaviridae Study Group of the International Committee on Taxonomy of V. The 455 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and 456 naming it SARS-CoV-2

A novel coronavirus from 458 patients with pneumonia in China

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven 461 protease inhibitor

Structure, function, 463 and antigenicity of the SARS-CoV-2 spike glycoprotein

Cryo-EM 465 structure of the 2019-nCoV spike in the prefusion conformation

Type 2 468 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

SARS-CoV-2 471 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Gastrointestinal 477 manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong 478 cohort: Systematic review and meta-analysis

Multiorgan and renal tropism of SARS-CoV-2

SARS-CoV-482 2 variants and vaccines

Immunostimulation with OM-85 in 484 children with recurrent infections of the upper respiratory tract: a double-blind, placebo-485 controlled multicenter study

Safety and efficacy of two courses of OM-85 BV in 487 the prevention of respiratory tract infections in children during 12 months

Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma 491 in children: a systematic review of mechanistic and clinical evidence

Enhanced mucosal antibody production and protection against respiratory infections following 495 an orally administered bacterial extract

Broncho Vaxom (OM-85) modulates rhinovirus 497 docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase 498 and cAMP

Airway 500 administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic 501 cells and the epithelium/IL-33/ILC2 axis

Mycoplasma 504 pneumoniae induces airway epithelial cell expression of MUC5AC in asthma

Protocol 507 and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for 508 neutralization assays

Titering lentiviral vectors: 510 comparison of DNA, RNA and marker expression methods

Lentivirus vectors 512 using human and simian immunodeficiency virus elements

CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is 515 detected in specific cell subsets across tissues

Animal and 517 translational models of SARS-CoV-2 infection and COVID-19

Drug repurposing screens 520 reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. 521 Cell Rep

523 Inhibition of SARS-CoV-2 by type I and type III interferons

CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract

Enhancing innate immunity against virus in times of 530 COVID-19: Trying to untangle facts from fictions

Bacterial Lysates as 532 Immunotherapies for Respiratory Infections: Methods of Preparation

Dexamethasone in 535 hospitalized patients with Covid-19

537 Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, 538 randomised controlled trial

Interleukin-6 receptor inhibition in Covid-19 -Cooling 540 the inflammatory soup

After 72 hours, cells were harvested, and a single cell suspension was

FACSWash buffer (PBS with 1% BSA and 0.1% NaN3) at 0.5-1x10 7 cells/ml

STAR: ultrafast 64 universal RNA-seq aligner

Normalization of RNA-seq data using factor 66 analysis of control genes or samples

Moderated estimation of fold change and dispersion for 68 RNA-seq data with DESeq2

Analysis of relative gene expression data using real-time 70 quantitative PCR and the 2(-Delta Delta C(T)) Method

Membrane Nanoparticles 72 Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection

Discovery of the natural product 74 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor

Inborn errors of 77 type I IFN immunity in patients with life-threatening COVID-19

Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad 80 Spectrum of Human Cell Lines through Multiple Entry Mechanisms

Seroprevalence of SARS-CoV-2 antibodies among rural healthcare workers

SARS-CoV-2 85 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and 86 Tweety family member 2

An infectivity-88 enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Vero cells were pretreated with PBS or OM-85 and then infected with SARS-CoV-2 (isolate USA-WA1/2020, 15 pfu/well) for 2 116 hours. Plaques were counted as described in Methods. Shown are average numbers ± 117 SEM of pfu detected in eight SARS-CoV-2-infected replicate wells pretreated with PBS 118 or increasing OM-85 concentrations. Data were pooled from two independent 119 experiments

(n=3-4 wells/condition, each run in triplicate) out of two. An unpaired, two-tailed t test 105 was used for statistical analysis after testing for normality of sample distribution. 106

Cells were treated with PBS or increasing OM-85 concentrations for 72 hours and then 108 incubated with or without recombinant His-tagged S1 protein, followed by an anti-His-109 PE antibody. S1 binding was assessed by flow cytometry. Data are shown as 110 percentages of S1 protein-binding cells in OM-85-treated versus PBS-treated cultures 111 (n=5-6 wells/group). An unpaired, two-tailed t test was used for statistical analysis after 112 testing for normality of sample distribution. 113 114